CordenPharma Expands Peptide Capacity

May 16, 2019
Article > CordenPharma Expands Peptide Capacity to Support Recent Market Trends

Article > CordenPharma Expands Peptide Capacity to Support Recent Market Trends

by Dr. Matthieu Giraud, Director, Global Peptides, Lipids & Carbohydrates Platform

Chemistry Today, Oligo & Peptide Supplement March / April 2019


The growing number of therapeutic peptides in clinical trials and a significant increase of therapeutic indications for peptides are the key drivers for capacity expansion by leading CDMOs (Contract Development & Manufacturing Organizations) in the global peptide API market. Although the early peptides were hormones, therapeutic peptides are now being developed for almost every therapeutic category ranging from anti-inflammatory to cancer therapeutics. Furthermore, CDMOs are focusing on internal and external capacity expansion and integration into the pharma supply chain, which ultimately increases contract manufacturing activities for peptide APIs across the globe.

The global peptide API market is estimated to be valued at US $1,700 Million in 2018, and likely to expand at a CAGR of 7.7% over the forecast period (2018–2025) to reach US $2,900 Million by 2025.

Global Peptide API Market Expansion 1.7 x Over 2018-2025

North America clearly dominated the global market with 47.9% value share in 2018, which represents the highest incremental opportunity of US$ 576.9 Million by 2025. In terms of value, the European market is expected to expand at the highest CAGR of 8.1% (2018-2025). However, in terms of volume, the APAC market is expected to witness the highest CAGR of 10.2% (2018-2025).

Read Full Article Online